Status:
WITHDRAWN
Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury
Lead Sponsor:
NYU Langone Health
Conditions:
ACL - Anterior Cruciate Ligament Rupture
ACL Injury
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this single-center, double-blinded randomized control trial with prospective data collection is to assess the ability of platelet rich plasma (PRP) treatment to reduce the level of pro-...
Eligibility Criteria
Inclusion
- Patients have suffered an acute ACL tear (initial presentation within 7 days of injury) with or without an associated meniscus injury
- Patient must undergo ACL reconstruction surgery
Exclusion
- Mentally impaired (e.g, Alzheimer's subjects, dementia, etc.)
- Younger than 18 years of age
- Patients who have a multiligamentous injury
- Patients with underlying inflammatory arthropathies
- Previous ACL injury and/or reconstruction
Key Trial Info
Start Date :
September 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03389685
Start Date
September 9 2018
End Date
February 1 2024
Last Update
April 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York University School of Medicine
New York, New York, United States, 10016